Camlin Fine Sciences Limited

Camlin Fine Sciences Subsidiary in Brazil Suffers Fire Incident at Blend Plant

A fire incident occurred at Camlin Fine Sciences' Brazilian subsidiary's Blend plant on February 7, 2026. Operations are stopped for assessment. The company has adequate insurance cover. Its other plant remains operational.

Camlin Fine Sciences to Host Q3 FY26 Earnings Call on Feb 13, 2026

Camlin Fine Sciences will host its Q3 & 9MFY26 Earnings Call on February 13, 2026, at 05:00 PM IST. Senior management, including the Chairman & MD and CFO, will discuss financial performance based on publicly available information.

Camlin Fine Sciences Faces Supreme Court Appeal on CGST Order

Camlin Fine Sciences has received a Supreme Court appeal from the CGST office challenging a High Court order. The appeal pertains to an IGST demand of ₹3.33 crore, including interest and penalty, for the period October 2017 to March 2022. The High Court had previously set aside this demand.

CFS Europe S.p.A., Subsidiary of Camlin Fine Sciences, Faces Liquidation Appeal

Camlin Fine Sciences' subsidiary, CFS Europe S.p.A., faces a liquidation appeal filed by its Board of Statutory Auditors. The appeal cites a lack of resources and inability to fund recovery investments. The company was notified on January 16, 2026.

Camlin Fine Sciences Increases Stake in Vinpai to 83.82% via Convertible Bond Conversion

Camlin Fine Sciences has increased its stake in Vinpai to 83.82% by converting EUR 33,00,000 in convertible bonds into 11,00,000 new ordinary shares. The transaction was completed on January 9, 2026. Vinpai, an ingredient'tech company, reported a turnover of €9.157 million in FY2024.

Camlin Fine Sciences Responds to Volume Spurt, Cites Free Trading

Camlin Fine Sciences Limited addressed a query from the NSE regarding a volume spurt. The company confirmed adherence to SEBI regulations for disclosures and stated it cannot comment on share price or volume movements due to free trading.

India Ratings Downgrades Camlin Fine Sciences' Bank Loan Facilities to IND BBB-/Stable/IND A3

India Ratings has downgraded Camlin Fine Sciences' bank loan facilities' long-term rating to IND BBB- and short-term rating to IND A3. The downgrade is due to expected weak performance in FY26, driven by higher costs and working capital needs in the vanillin business. Promoters infused ₹2,250 million in FY25.

Camlin Fine Sciences Files SEBI Compliance Certificate for Q3 FY26

Camlin Fine Sciences Limited submitted a compliance certificate for the quarter ended December 31, 2025. The certificate from MUFG Intime India Private Limited confirms the processing of dematerialised securities and adherence to SEBI regulations.

Camlin Fine Sciences Receives Tax Order for ₹48.59 Lakh Demand

Camlin Fine Sciences received a tax order demanding ₹48.59 lakh for ineligible ITC, plus interest and a 50% penalty. The order relates to FY18-19 and FY19-20. The company believes there's no material impact and plans to appeal.

Camlin Fine Sciences Adjusts Vinpai Tender Offer Timetable to End-Feb 2026

Camlin Fine Sciences will file its mandatory tender offer for Vinpai shares by end-February 2026, delayed due to Indian regulatory approvals. The company acquired a majority stake on Nov 27, 2025, and expects to hold 83.82% of Vinpai's capital post-convertible bond conversion by Dec 31, 2025.

Camlin Fine Sciences: Trading Window Closed Jan 1, 2026 for Q3 FY26 Results

Camlin Fine Sciences will close its trading window from January 1, 2026. This is in anticipation of the declaration of un-audited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The window will reopen 48 hours post-declaration.

Camlin Fine Sciences shareholders approve reappointment of Director Mahabaleshwar G. Palekar

Camlin Fine Sciences Limited shareholders approved the re-appointment of Mr. Mahabaleshwar G. Palekar as Non-Executive Independent Director for a second five-year term starting December 24, 2025. The resolution passed with a significant majority via postal ballot, with over 99.96% of votes in favour.

CAMLINFINE: Allotment of 41,06,181 Equity Shares for Vinpai Acquisition

Camlin Fine Sciences allotted 41,06,181 equity shares at ₹247.69 per share to acquire Vinpai shares, increasing equity share capital from ₹18.80 crore to ₹19.21 crore.

Camlin Fine Sciences Allots 41,06,181 Equity Shares for Vinpai Acquisition

Camlin Fine Sciences allots 41,06,181 equity shares at ₹247.69 each, totaling ₹101.70 crore, for acquiring Vinpai shares, increasing equity capital to ₹19,20,86,613. The acquisition of 78.68% stake in Vinpai is now complete.

Camlin Fine Sciences Allots Equity Shares for Vinpai Acquisition

Camlin Fine Sciences allots equity shares worth ₹101.70 crore for the acquisition of Vinpai, increasing its equity share capital.

CFSL Completes Acquisition of Majority Stake in Vinpai; To Launch Tender Offer

Camlin Fine Sciences completes acquisition of 78.68% stake in Vinpai. To launch tender offer for remaining shares and allocate consideration shares on November 30, 2025.

Camlin Fine Sciences Updates on Vinpai Acquisition Schedule

Camlin Fine Sciences provides an update on the acquisition of a majority stake in Vinpai, with Indian regulatory approvals received and allotment of CFSL Consideration Shares expected by November 30, 2025.

Camlin Fine Sciences publishes postal ballot notice for independent director's re-appointment

Camlin Fine Sciences published the postal ballot notice for the re-appointment of Mr. Mahabaleshwar G. Palekar as an Independent Director for a second term. E-voting is from November 14 to December 13, 2025. Results by December 15, 2025.

Camlin Fine Sciences Q2 & H1 FY'26 Earnings Call Transcript

Camlin Fine Sciences' Q2 FY26 earnings call reveals ₹460Cr revenue, 8.6% growth, and strategic moves including a French acquisition. Volumes increased, but tariffs impact Vanillin realization. Optimistic outlook for blends and Vanillin sales.

Postal Ballot for Re-Appointment of Independent Director

Camlin Fine Sciences announces postal ballot for re-appointment of Mr. Mahabaleshwar G. Palekar as a Non-Executive Independent Director, with e-voting from November 14 to December 13, 2025.

Newspaper Publication of Un-audited Financial Results for Quarter Ended Sep 30, 2025

Camlin Fine Sciences Limited announced the publication of its Un-audited Financial Results (Consolidated and Standalone) for the quarter and half year ended September 30, 2025, in newspapers.

Camlin Fine Sciences releases audio recording of Q2/H1 FY26 results conference call

Camlin Fine Sciences released the audio recording of its November 10, 2025 concall discussing Q2 and H1 FY26 un-audited financial results for investors on its website.

Monitoring Agency Report for Quarter Ended September 30, 2025

Camlin Fine Sciences submits Monitoring Agency Report for quarter ended September 30, 2025, confirming no deviation in utilization of funds raised through Rights Issue.

Camlin Fine Sciences Announces Investor Presentation

Camlin Fine Sciences disclosed investor presentation on November 10, 2025, related to the discussion about unaudited financial results for the quarter and half year ended September 30, 2025.

Camlin Fine Sciences Approves Re-appointment, Grants ESOPs, and Reports Q2 Results

Camlin Fine Sciences approves Q2 results, re-appoints director, grants ESOPs, and sets postal ballot. Palekar's re-appointment is from Dec 24, 2025, to Dec 23, 2030. Granted 16,23,000 ESOPs.

CAMLINFINE Approves Unaudited Financial Results, Re-appointment of Director & ESOP

CAMLINFINE approves unaudited financial results for the quarter ended September 30, 2025, re-appointment of director, and ESOP grant.

Camlin Fine Sciences Announces Investor Conference Call on November 10, 2025

Camlin Fine Sciences to hold a conference call on November 10, 2025, to discuss financial results for the quarter ended September 30, 2025. Key management to participate.

Camlin Fine Sciences Shareholders Approve Preferential Equity Share Issuance via Share Swap

Camlin Fine Sciences shareholders approved the preferential issuance of equity shares through a share swap arrangement via postal ballot on October 29, 2025, with 99.99% votes in favor.

Corrigendum to Postal Ballot Notice regarding preferential issue

Camlin Fine Sciences issues corrigendum to postal ballot notice for preferential issue related to Vinpai acquisition, addressing exchange clarifications. Members can update votes until October 29, 2025.

Camlin Fine Sciences issues corrigendum for preferential issue related to Vinpai acquisition

Camlin Fine Sciences issued a corrigendum to its postal ballot notice regarding the preferential issue for acquiring a 78.68% stake in France-based Vinpai, allowing members to amend votes by October 29, 2025.

Certificate under SEBI Regulations for Quarter Ended September 30, 2025

Camlin Fine Sciences Limited submitted a certificate under SEBI Regulations for the quarter ended September 30, 2025, confirming the dematerialization of securities.

Camlin Fine Sciences to issue shares worth ₹101.71 crore for Vinpai acquisition

Camlin Fine Sciences Extends Vinpai S.A. Acquisition Timeline

Camlin Fine Sciences corrects discrepancy in FY25 financial results filing

Re-appointment of Mr. Joseph Conrad D’Souza as Non-Executive Independent Director

Bombay HC quashes order for IGST refund recovery of ₹3.33 crore

Camlin Fine Sciences reports Q1 FY26 results; approves director re-appointment and management changes

Camlin Fine Sciences to hold conference call on 8 Aug 25 to discuss Q1 FY26 results